We believe there is tremendous upside for investors by owning Epigenomics ahead of, what we expect to be, a positive CMS reimbursement decision by August 28th. Read more.
IMPORTANT - ASSUME BIAS
Treat what you read here as biased. Encode Ideas, LP and its principals may hold positions in any company covered, may have current or past compensated relationships with covered companies, and may be pursuing such relationships. Our analysis is influenced by all of the above - actual positions, current relationships, past relationships, and prospective relationships. Assume errors. Nothing herein is investment advice. See encodelp.com/disclosure for current and past sponsor relationships.